Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.44 |
| ▸ | CTSL | P07711 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20164153 | 1.00 | MAPT (0.46) | MAPTLMNATGM2CTSSCTSL | |
| SCHEMBL20164183 | 0.84 | KEAP1 (0.35) | CTSLCTSB | |
| SCHEMBL20164177 | 0.83 | MAPT (0.44) | MAPTLMNACTSSCTSLCTSK | |
| SCHEMBL20164176 | 0.83 | MAPT (0.44) | MAPTLMNACTSSCTSLCTSK | |
| SCHEMBL20164191 | 0.83 | CTSS (0.44) | MAPTLMNACTSSCTSLCTSK | |
| SCHEMBL20164188 | 0.83 | CTSS (0.44) | MAPTLMNACTSSCTSLCTSK | |
| SCHEMBL18330319 | 0.77 | CTSS (0.40) | MAPTLMNATGM2CTSSCTSL | |
| SCHEMBL17102165 | 0.76 | CASP3 (0.47) | TGM2CTSSCTSLCTSKCTSB | |
| SCHEMBL12873774 | 0.74 | CTSL (0.54) | CTSSCTSLCTSKCTSBALDH1A1 | |
| SCHEMBL924114 | 0.74 | PPARA (0.53) | CTSSCTSLCTSKCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026083-B | Diamide macrocycles as factor XIA inhibitors | 百时美施贵宝公司 | 2021-08-27 | — | — | CN | disclosed |
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-3310777-B1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | MAPT 569/4885LMNA 2365/4885TGM2 2545/4885 |
| US-10160750-B2 | Diamide macrocycles as factor XIa inhibitors | TFPI, TFPI2, F11 | MAPT 569/4885LMNA 2365/4885TGM2 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.